ATH434 Slows Functional Decline in MSA by 52% in Phase 2 Trial, Phase 3 Ahead
Alterity's iron-targeting drug ATH434 slowed functional decline by roughly 52% in multiple system atrophy, advancing to a Phase 3 pivotal trial.
Summary
Alterity Therapeutics reported new analyses from its Phase 2 trial of ATH434, a drug designed to reduce toxic iron accumulation in the brain, in patients with multiple system atrophy (MSA), a rare and rapidly progressive neurodegenerative disease. When researchers accounted for baseline levels of cerebrospinal fluid neurofilament light chain — a marker of nerve damage — the 50 mg dose of ATH434 produced roughly a 52% slowing of functional decline compared to placebo over 52 weeks. The primary imaging endpoint was not met, but regional iron redistribution signals were detected. The drug was well tolerated with no serious drug-related adverse events. Based on these results, Alterity is moving forward with a Phase 3 pivotal trial in MSA.
Detailed Summary
Multiple system atrophy is a fatal neurodegenerative disease with no approved disease-modifying treatments, making it a critical unmet need in brain health and aging medicine. ATH434, developed by Alterity Therapeutics, works by chelating excess iron in the brain — a mechanism increasingly implicated in neurodegeneration and cellular aging — potentially protecting neurons from oxidative damage and slowing disease progression.
In the Phase 2 ATH434-201 trial, 77 adults were randomized in a double-blind, placebo-controlled study over 12 months. When baseline cerebrospinal fluid neurofilament light chain (CSF NfL) — a validated biomarker of neurodegeneration — was included as a covariate in the statistical model, the 50 mg ATH434 group showed a −4.64 point difference versus placebo on the UMSARS Part I functional scale at 52 weeks (p=0.032). This translates to approximately 52% slowing of functional decline in a modified intent-to-treat population of 61 participants.
CSF NfL itself emerged as a strong predictor of clinical worsening: each 1,000 pg/mL increase in baseline NfL was associated with an additional 0.9 points of deterioration (p=0.033), reinforcing its utility as a stratification biomarker in future trials. The primary imaging endpoint — reduction in substantia nigra iron via quantitative susceptibility mapping — was not met, though a statistically significant increase in dentate nucleus iron (+0.016 ppm, p=0.021) with the 50 mg dose was observed, which the company interprets as possible iron redistribution rather than net accumulation.
The safety profile was favorable, with adverse event rates similar between ATH434 and placebo and no serious drug-related adverse events reported. These results provide a rationale for the planned Phase 3 pivotal trial.
Caveats are important: the positive functional outcome required post-hoc covariate adjustment and a modified analysis population, meaning the trial did not meet its original primary endpoint. Phase 3 will be the true test of whether ATH434 delivers a robust, clinically meaningful benefit for MSA patients.
Key Findings
- ATH434 50 mg slowed functional decline by ~52% vs. placebo on UMSARS Part I at 52 weeks after CSF NfL adjustment.
- Higher baseline CSF NfL predicted faster clinical decline, supporting its use as a stratification biomarker in future trials.
- Primary imaging endpoint for substantia nigra iron reduction was not met; dentate nucleus iron change was statistically significant.
- ATH434 was well tolerated with no serious drug-related adverse events across 77 participants over 12 months.
- Alterity is advancing to a Phase 3 pivotal trial in multiple system atrophy based on these Phase 2 findings.
Methodology
This is a news report summarizing company-presented analyses from a randomized, double-blind, placebo-controlled Phase 2 trial (N=77) at the 2026 International Congress of Parkinson's Disease and Movement Disorders. Data are company-reported and have not yet been independently peer-reviewed. The positive functional outcome relied on a post-hoc covariate adjustment and a modified intent-to-treat population rather than the pre-specified primary endpoint.
Study Limitations
The key functional finding required post-hoc statistical adjustment and a reduced analysis population, meaning the trial did not meet its pre-specified primary endpoint — this substantially limits the strength of the inference. All data are currently company-reported from a conference presentation, not a peer-reviewed publication, so independent verification of methods and results is essential. The trial was conducted in a rare disease population; generalizability to broader neurodegenerative conditions remains unestablished.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: